By IDSE News Staff
The FDA agreed to review a supplemental New Drug Applications (sNDAs) for Merck’s Pifeltro and Delstrigo, both doravirine-based antiretroviral therapy (ART) drugs.
The applications seek approval for both medications to be used in people living with HIV-1 who are switching from a stable antiretroviral regimen and whose virus is suppressed (HIV-1 RNA <50 copies/mL).